Given that the company said that it now expects a ‘period of sustained growth for years to come’ there is going to be a lot of pressure on Thursday’s full year results to show that the sales surge wasn’t a one-off. AstraZeneca is expecting a ‘low single-digit’ percentage increase in product sales for the full year, alongside core earnings per share of between $3.30 and $3.50. Its guidance for the new financial year could also be key.

Read what Spreadex analysts have to say, or watch a 60 second earnings preview video, here:

Unlock the rest of this Article in 15 seconds

or Unlock with your email

Already have an account?
Login here